US expands scope of Seattle Genetics’ Adcetris
US regulators have approved Seattle Genetics’ Adcetris in combination with chemotherapy for adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma.
Read More
Tag: cHL
NICE backs Opdivo for classical Hodgkin lymphoma
Patients with classical Hodgkin lymphoma (cHL) living in England and Wales could now become the first to get routine access on the NHS to Bristol-Myers Squibb’s immunotherapy Opdivo after a u-turn saw cost regulators provisionally back the drug.
Read More
MSD’s Keytruda wins EU green light in Hodgkin lymphoma
European regulators have expanded the reach of MSD’s Keytruda to include some patients with classical Hodgkin lymphoma (cHL), a type of lymphoma that develops in white blood cells of which there are around 66,000 new cases around the globe every year.
Read More
MSD’s Keytruda closer to classical Hodgkin Lymphoma nod
MSD’s anti-PD-1 therapy Keytruda has taken a giant leap towards being approved in Europe for the treatment of classical Hodgkin Lymphoma (cHL).
Read More
US approves Merck’s Keytruda for Hodgkin lymphoma
Merck’s immunotherapy Keytruda has been approved by US regulators to treat both adult and paediatric patients with refractory classical Hodgkin lymphoma (cHL), or those who have relapsed after three or more prior lines of therapy.
Read More
EU green light for BMS’ Opdivo in blood cancer
EU regulators have issued a green light for the use of Bristol-Myers Squibb’s Opdivo to treat the rare and often aggressive blood cancer classical Hodgkin lymphoma (cHL).
Read More
MSD drops price of Keytruda for NICE nod
New data and a price reduction have helped secure a place for Keytruda on the NHS as a treatment for some patients with lung cancer.
Read More
EU approves Opdivo for Classical Hodgkin’s Lymphoma
European regulators have expanded the scope of Bristol-Myers Squibb’s immunotherapy Opdivo, approving its use to treat certain patients with Classical Hodgkin Lymphoma (cHL).
Read More
UK cHL patients get early access to Opdivo
UK patients with a certain form of blood cancer will get access to Bristol-Myers Squibb’s immunotherapy Opdivo through the Early Access to Medicines Scheme (EAMS), ahead of its European licence.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
